Sutimlimab
- Generic Name
- Sutimlimab
- Brand Names
- Enjaymo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2049079-64-1
- Unique Ingredient Identifier
- GNWE7KJ995
- Background
Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures. This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly. In approximately 90% of cases, patients develop immunoglobulin M ...
- Indication
Sutimlimab is indicated to treat hemolysis in adults with cold agglutinin disease (CAD) and decrease the need for red blood cell transfusion in these patients.
- Associated Conditions
- Hemolysis
- Associated Therapies
- -
Cold Agglutinin Disease Real World Evidence Registry
- Conditions
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 400
- Registration Number
- NCT05791708
- Locations
- 🇺🇸
Mission Hope Medical Oncology Site Number : 1241, Santa Maria, California, United States
🇺🇸Hematology Oncology Associates, PC Site Number : 1211, Medford, Oregon, United States
🇫🇷Investigational Site Number : 3211, CHALON SUR SAONE Cedex, France
Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT05132127
- Locations
- 🇯🇵
Investigational Site Number 3920003, Osaka, Japan
🇯🇵Investigational Site Number 3920002, Saitama, Japan
🇯🇵Investigational Site Number 3920001, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.